SEATTLE, Nov. 2 /PRNewswire-FirstCall/ -- Dendreon Corporation will release its third quarter financial results on Thursday, November 15, 2007. Company management will host a conference call at 1:30 p.m. PT; 4:30 p.m. ET to review financial results and provide a general corporate update. Access to the discussion may be obtained as follows:
http://www.dendreon.com
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-888-203-1112 or +1-719-457-0820 for international callers; the conference ID number is 5547646. The replay will be available from 7:30 pm ET on Thursday, November 15 until 11:59 pm ET on Saturday, November 17. In addition the webcast will be archived for on-demand listening for 30 days at http://www.dendreon.com.
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has headquarters in Seattle and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.
CONTACT: Jennifer Williams, Investor Relations of Dendreon Corporation,
+1-206-829-1500
Web site: http://www.dendreon.com/
